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Background
Interstitial fibrosis is the common pathophysiological
mechanism that leads to end organ failure of the both the
heart and the kidney. Fibrosis is characterized by an exces-
sive accumulation of myofibroblast-derived extracellular
matrix. Peritubular capillary rarefaction precedes renal
fibrosis and is secondary to the loss of capillary pericytes
to the interstitium. Endothelial-derived C-type natriuretic
peptide (CNP) has been demonstrated to have cGMP
dependent anti-fibrotic properties most likely due to the
interference with pro-fibrotic TGF-b signaling and may
counteract the loss of the capillary pericytes. However,
natriuretic peptides like CNP are rapidly degraded by neu-
tral endopeptidase (NEP). In a unilateral urether obstruc-
tion (UUO) mouse model for kidney fibrosis we assessed
the anti-fibrotic effects of Sol-1, a new orally-active com-
pound (Solvay) that inhibits both neutral endopeptidase
and endothelin.
Results
Mice (n=10 per group) subjected to UUO were treated for
1 week with either Solvent, SOL-1 (NEP-/ECE-inhibitor
two doses), candoxatril (reference NEP inhibitor) or losar-
tan (angiotensin AT1-receptor antagonist) and compared
to sham operated animals. While the NEP inhibitors had
no significant effect on body weight, food and water
intake, mean blood pressure or creatinine levels, they did
increase cGMP levels in the urine and affected hematopoi-
esis in an anti-inflammatory way. Also immunohistochem-
ical staining revealed a marked decrease in collagen (from
1.8%±1.4% to 0.8%±0.3%, P<0.05) and a-SMA (from 8.3%
±3.8% to 4.9%±1.9%, P<0.05). Moreover, a-SMA deposi-
tion in the kidney cortex was inversely correlated with
cGMP elevation suggesting a NEP dependent antifibrotic
effect.
To further dissect the molecular mechanisms underlying
the anti-fibrotic effects of Sol-1 we performed a “Deep
SAGE” transcriptome analyses total kidney samples of all
treatment groups. High quality mRNA profiles were
obtained with at least 8 independent samples per treat-
ment group. The data confirms the cGMP dependent
anti-fibrotic action of Sol-1 and further supports the
potential therapeutic actions of this neutral endopeptidase
inhibitor.
Conclusion
A neutral endopeptidase inhibitor candoxatril and double
NEP-/ECE-inhibitor SOL-1 increased cGMP levels,
decreased a-SMA content in the kidney cortex and there-
fore showed antifibrotic properties in the mouse model of
UUO.
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